INTRODUCTION
Porphyrin metabolism in humans has been extensively investigated, particularly in the occurrence of a group of clinically-related diseases known as porphyrias, arising from genetic defects (1) of the enzymes in heme biosynthesis causing accumulation of various heme precursors (2, 3) . The commonest porphyric disorder, porphyria cutanea tarda, and its related forms are characterized by massive hepatic accumulation and increased excretion of uroporphyrin (URO) and to a lesser extent other types of porphyrins such as coproporphyrins and isocoproporphyrins (4) . A number of etiological factors such as iron overload (5), ascorbic acid deficiency (6) , hepatitis c infection (7) , alcohol abuse (8) and induction of CYP isoenzymes (9) have been suggested to be the cause of the sporadic form of the diseases. Of the many possible URO isomers, only type I and III occur in nature. Both isomers arise from spontaneous oxidation of the heme metabolic intermediates, uroporphyrinogen (UROgen) I and III. UROgen III synthase catalyzes the conversion of hydroxymethylbilane to UROgen III which involves rearrangement of the propionate and acetate groups of ring IV of the tetrapyrrole, whereas
EXPERIMENTAL PROCEDURES
Unless stated otherwise, all chemicals were purchased from Sigma Chemicals.
Clotrimazole, Triadimefon and Miconazole were kindly donated by Dr E. I. Mercer (University of Wales, Aberystwyth). UROgen III was obtained from Frontier Scientific (UK).
Electrophoresis reagents were purchased from BioRad Labs (Herts, UK) and BDH (Poole, UK).
Heterologous expression, quantification and isolation of CYPs
In the present study we employed E. coli TB1 {F, ara∆(lac-proAB)rps φ 80d lacZ∆M15hsdR17 (r k + m k + )} strain harbouring pLi-CYP105D1 encoding the secretory form of CYP105D1, pAA-CYT coding for the secretory form of mammalian cytochrome b 5 (16, 17) , pIN-CYP105 expressing the cytosolic CYP105D1 and the control progenitor plasmid pLi-Q (15). Plasmid pIN-CYP105D1 is a derivative of pLi-CYP105D1 and lacks the signal sequence. The vector was constructed by an inverse PCR strategy using pLi-CYP105D1 as the template and the following primers:
5' ATGACGGAATCCACGACGG
5' TTTATTTTCTCCATGTACAAATAC
The amplified DNA duplex was circularised by T4 DNA ligase and introduced into E. coli TB1.
For induction of recombinant proteins, a 2% (v/v) inoculum of Luria Bertani broth-grown, saturated culture was added to a phosphate-limited (0.1 mM) MOPS medium (16) containing 75
µg ampicillin/ml. The culture was batch-cultivated at 35 o C with orbital agitation at 125 rpm for periods specified elsewhere in the text. Unless stated otherwise, 5-aminolevulinic acid (ALA) at 1 mM was routinely included in the MOPS growth media.
All media used for subcellular fractionation or isolation of URO contained 5 mM ascorbic acid in order to reduce adventitious auto-oxidative generation of porphyrin. Periplasm extracts by guest on http://www.jbc.org/ Downloaded from were isolated as described previously (15). To verify that authentic isolation of the periplasm had occurred, marker enzymes known to be specific for each of the sub-cellular fraction were routinely assayed as described (16) . CYP content in biological samples were estimated according to the procedure described by Omura and Sato (18) using an absorption coefficient of 91 mM
. The oxidised cytochrome b 5 was quantified from the Soret absorption peak at 413 nm using the absorption coefficient of 115 mM -1 cm -1 (19) . Protein content was estimated employing the Bio-Rad protein assay (Bio-Rad, UK) using bovine serum albumin as the standard (20) .
The CYP105D1 enzyme was purified from the periplasmic extract of E. coli CYP105D1
(1 Lit culture) cultivated for 24 h at 28 o C with 1 mM ALA supplementation. Following two-fold dilution of the periplasmic extract with 10mM Tris-acetate (pH 8) buffer (TA) containing 1 mM EDTA, the sample was applied twice through a TA-pre-equilibrated column of DEAE CL-6B Sepharose (5 ml bed volume). The column was successively washed with 5 ml of (i) TA,
(ii) 0.1 M NaCl in TA and (iii) 0.3 M NaCl in TA. The enzyme was eluted with 25 ml 0.5 M NaCl in TA. The solution was concentrated by pressure filtration to 2.5 ml and the CYP105D1 further purified by FPLC by passage through a Superose column (1.5 cm x 65 cm) with 50 mM
Tris-HCl (pH 7.5) buffer. The flow rate was 1 ml/min and fractions of 2 ml were collected.
CYP105D1-enriched fractions were pooled and concentrated using an Amicon Centricon 10 micro-concentrator (LKB-Pharmacia, UK).
Isolation and estimation of URO Periplasmic and cytoplasmic extracts were derived from E.
coli cultured in 100 ml MOPS media supplemented with ALA and 75 µg ampicillin/ml. Each extract, finally recovered in 5 ml TA, was acidified with HCl to 0.2 M final concentration (pH < 2) and left on ice for 5 min. The deproteinised supernatant was recovered by by guest on http://www.jbc.org/ Downloaded from centrifugation at 13,000 g for 2 min. The URO in the supernatant fraction after appropriate dilution were estimated spectroscopically from absorbance at 406 nm using the absorption coefficient 541 mM -1 cm -1 (21) . The values were standardized to nmol/ L culture.
For estimation of URO in the 'spent' growth medium, 20 ml of the growth medium was applied onto a DEAE CL-6B Sepharose column (1 ml bed volume). After washing the column with 5 ml of 0.3 M NaCl in TA, the pigments were eluted with 2 ml 1 M NaCl in TA, acidified and spectroscopically quantified as described above.
For the analysis and estimation of URO by HPLC (22) , the periplasmic fraction (5 ml volume recovered from 100 ml culture) was first de-proteinised with 0.2 M HCl as described above. The pH of the supernatant was adjusted to 7.5 by titration with Trizma base. Following five-fold dilution with distilled water, the solution was applied onto a DEAE Sepharose CL-6B column (1 ml bed volume). After washing the column with 5 ml TA, the pigments were eluted with 1 ml 1 M NaCl in TA. HPLC was performed on an ODS2 column (250 mm x 4.6 mm; 5 µm 
URO accumulation is confined to the periplasm and concomitantly coupled with the exported holo CYP105D1
The quantities of URO in the periplasm and cytoplasm compartments and in the growth media of E. coli strains harbouring pLi-Q or pLi-CYP105D1 cultured in the presence of 1 mM ALA were monitored as a function of time (Table 1) . In both strains, the periplasmic URO accrued with the duration of culturing. However, the control pLi-Q strain showed only a fivefold increase ranging from 2 nmol/Lit culture at 12 h to about 10 nmol URO /Lit culture at 36 h compared to an approximately 100-fold increase in URO in the recombinant strain. The latter produced 800 nmol URO/L by 36 h. In the pLi-Q strain, URO profile followed a similar pattern to that seen in its periplasm. In contrast, the cytoplasmic level of URO in pLi-CYP105D1
increased substantially by nearly ten-fold, reaching 25 nmol URO/Lit culture following 36 h of culturing. Given the high accumulation of URO in the periplasm, we cannot discount the likelihood that URO in the cytoplasmic fraction could be, at least partly, derived from contamination during cellular fractionation or in vivo leakage from the periplasm. In contrast, the URO found in the growth media in the control and pLi-CYP105D1-expressing strains were negligible (Table 1) .
We considered the possibility that over-expression and export of the apo CYP105D1 may have induced synthesis and periplasmic export of heme. This possibility was explored by measuring the periplasmic and cytoplasmic pools of URO in an E. coli TB1 strain pAA-CYT that efficiently exports a mammalian recombinant cytochrome b 5 under comparable expression conditions to CYP105DI (16) . Interestingly, although cytochrome b 5 is produced at about a 10-fold molar (24 h) excess over CYP105 (Table 2) , the periplasmic, cytoplasmic and medium URO by guest on http://www.jbc.org/ Downloaded from levels in this strain are similar to those in the control pLi-Q strain throughout the duration of culturing (Table 1) .
To investigate whether URO production was an event specifically coupled with expression of the periplasmic form of CYP105D1, we constructed a cell line that expressed a non-secreted, cytoplasmic CYP105D1. The cytoplasmic CYP105D1 was expressed more efficiently than the secretory form ( Table 2 ) and supported URO formation, though to a significantly lesser extent than that catalysed by the periplasmic catalyst ( Table 1) . Identities of the URO accumulated in the periplasmic fractions of the control and recombinant strain was confirmed by subjecting de-proteinated extracts to HPLC analysis. Using the standard conditions described under Experimental Procedures, URO (I and III) were clearly resolved and URO I was the dominant species. The overall pattern and yields of URO detected by HPLC were similar to that monitored spectroscopically in the periplasmic extracts.
URO production requires exogenous ALA and co-expression of holo CYP105D1
In view of the long periods (> 12 h) required to generate significant URO production, it was of interest to explore whether this phenomenon was related to synthesis and /or assembly of CYP105D1 in the periplasm. Hence, this necessitated an investigation on ALA dependency on production of holo and apo CYP105D1 (Fig. 5) . The periplasmically-recovered soluble CYP105D1 was separated by non-denaturing gel electrophoresis. The apo and holo forms were detected and distinguished by a combination of heme-staining and Western blotting using anti- coli pLi-CYP105D1 occurred only in the presence of exogenously-supplemented ALA (Fig. 6 ).
Peak production of URO was reached at 0.25 mM ALA and at higher doses inhibition was imposed. Interestingly, supplementation of the cultures with additional ALA at 12 h slightly enhanced the productivity of URO but beyond 0.2 mM ALA a more drastic inhibition of URO was imposed (Fig. 6 ). In contrast, formation of holo CYP105D1 was more directly proportional to ALA concentration up to 0.8 mM such that at the highest tested concentration of 2 mM ALA, a 20-fold increase in holo hemoprotein was reached ( Figs 5 and 6 ). These findings suggest that formation of both holo CYP105D1 and URO production were clearly dependent upon ALA supplemented in the medium except that in the latter case a higher concentration of ALA caused a decrease in URO accumulation for reasons which are not clear.
Selective fungicides inhibit URO production
We investigated the effects of the fungal P450 inhibitors, clotrimazole, miconazole and triadmefon , which interfere with the sterol biosynthesis (28) on the productivity of URO. These compounds are well known to exert their inhibitory effects by interacting with the heme iron of CYPs (29) . Standard batch cultures were incubated with the inhibitors at concentrations ranging from 0 to 2.5 mM, and the periplasmic URO monitored after 24 h of culturing (Fig. 7) .
clotrimazole at 0.5 mM produced the most pronounced decline (65%) in URO accumulation.
However, all of the inhibitors suppressed URO production in a dose-dependent manner and yielded a similar inhibition of about 60% at 2.5 mM azole. 
DISCUSSION
In the present study we have investigated the formation of a fluorescent pigment in E. coli TB1 strain in ALA-treated cells expressing a secreted or periplasmic-localized CYP105D1. The pigment has been firmly identified by absorption and fluorescence spectroscopy, electron-spray ionisation and HPLC. Several pieces of evidence strongly point to catalytic involvement of CYP105D1 in the transformation of UROgen I to URO I. Over a hundred-fold higher level of URO was found in E. coli pLi-CYP105D1 than in the comparable control harbouring pLi-Q or pAA-CYT ( Table 1 ). The azole compounds, known to be potent inhibitors of CYPs, considerably reduced the in vivo productivity of URO in the recombinant but not in the nonrecombinant cell lines (Fig. 7) . In contrast to the control strain pLi-Q and another overexpressing, secreted hemoprotein, cytochrome b 5 , production of URO I was most effective in E.
coli harbouring pLi-CYP105D1 expressing the periplasmicaly-localised CYP105D1.
Nevertheless, a small but significantly elevated production of URO was also observed in the cytosolic-expressing CYP105D1 cells (Table 1) . Thus, we conclude that periplasmic targeting of the catalyst was a pre-requisite for generating a uroporphyric-like state. This raises interesting issues regarding the temporal nature of periplasmic CYP-catalysed conversion of UROgen I to URO I in E. coli. The important points to address are: (i) the derivation of the substrate from the heme biosynthetic pathway in the cytosol (ii) the preferential generation of URO I rather than URO III isomer (iii) the likely mechanism(s) by which UROgen I reaches the periplasm for the CYP105D1-catalysed conversion to URO I, and (iv) the nature of electrons source and the likely mechanism of the transformation by CYP105D1.
ALA is the first committed precursor of tetrapyrrole synthesis and its intracellular concentration limits the rate of porphyrin synthesis in E. coli (31) . In prokaryotes, ALA synthase is a regulatory enzyme whose activity can be repressed by heme feed-back inhibition. However, exogenously-supplied ALA can cause an overproduction of porphyrins (32, 33) and heme as shown in this study. However, it seems unlikely that uroporphyrin accumulation merely resulted from increased hemoprotein synthesis since over-expression at ten-fold molar excess over the exported CYP105D1 of the periplasmically-exported hemoprotein, the globular core of cytochrome b 5 , failed to promote porphyrin production. Expression of the substantial amounts periplasmic apo CYP105D1 and its conversion to holo form demands a higher than normal cellular heme supply which is derived from exogenously-supplied ALA in the growth medium (Figs. 5 and 6). In the absence of ALA only a small proportion (< 10%) of the expressed CYP105D1 was converted to the holo form (Fig. 5) . Exogenous heme supplementation in the culture medium did not improve the generation of holo CYP105D1 suggesting that the prosthetic group was not made available in the periplasm of E. coli TB1 cells as previously reported for the secreted form of cytochrome b 5 (34) and that the outer membrane of E. coli is normally impermeable to heme (35) . Nevertheless, the alleviation of this heme deficiency by ALA supplemented in the culture medium (Figs. 5 and 6) indicated that heme, during the assembly of CYP in E. coli, was derived metabolically via the de novo pathway (36) . This suggests that the limiting step in heme synthesis during overproduction of CYP105D1 occurs at or prior to ALA synthesis (37) . Thus, excess ALA is required to produce maximal holo CYP which when expressed periplasmically produces massive URO accumulation.
The second issue relates to the question of preferential periplasmic accumulation of URO I rather than the III isomer with co-expression of periplasmic CYP105D1. Indeed both URO I and URO III can accumulate either in the presence or absence of ALA under some circumstances in a variety of cells. Moreover, the UROgens, which are the true intermediates, also need to be by guest on http://www.jbc.org/ Downloaded from oxidized to generate the porphyrins. The production of all heme intermediates would be expected to occur exclusively in the cytosol where the complete hem-encoded pathway is localised.
Hydroxymethylbilane synthase (porphobilinogen deaminase) condenses four porphobilinogen molecules to form the first linear tetrapyrrole, hydroxymethylbilane (38) . Hydroxymethylbilane, being unstable in solution can non-enzymatically cyclize to form UROgen I which is a physiologically redundant end product. However, hydroxymethylbilane is normally rapidly converted to UROgen III by the action of UROgen III synthase (39) . Both I and III forms of
UROgens have the potential to be oxidised to their respective porphyrin forms in the cytosol, although this apparently does not occur to a large extent under the physiological conditions studied here. UROgen III would be expected to be removed by the action of UROgen decarboxylase and its auto-oxidative conversion to URO III may be partly suppressed due to a higher reducing condition within the cytoplasm. Whilst UROgen I may also accumulate in the cytosol and/or periplasm, UROgen III can be removed by the action of UROgen III decarboxylase, to be eventually converted to heme. Although the accumulated UROgen I can also be decarboxylated by UROgen decarboxylase to give coproporphyrinogen I, we are unable to explain why the oxidized intermediate, coproporphyrin I was not observed here. Nevertheless, the findings imply that UROgen III decarboxylase is absent in the periplasm. A plausible model of the likely metabolic events is depicted in Fig. 8 . enhanced oxidation by CYP105D1 in the more amenable oxidising environment of the periplasm (Fig.8) .
The periplasmic reaction involving production of URO I would be expected to require reducing equivalent(s) and molecular oxygen for the P450 catalysis and a yet unidentified reductase system to transfer the reducing equivalents to CYP105D1. Reducing equivalents such as NADH or NADPH are unlikely to be present in periplasmic space but they could be scavenged from the electron transport chain or other periplasmic oxido-reductant reactions.
However, electron transfer to the heterologous CYP105D1 must require a reductase, most likely a ferredoxin reduction type system. Genomic analysis of E. coli suggests presence of a periplasmic ferrodoxin-type reductase which uses a TAT-dependent export pathway (41) . The removal of six hydrogen atoms from UROgen I, two from the pyrrolic nitrogens and four from the methene carbons would result in the formation of URO I. As yet, the mechanism for the mediation of UROgen oxidation by CYP remains unknown.
Clearly, ALA-dependent URO I production can be induced in a recombinant E. coli expressing periplasmic CYP105D1 and we have made similar observations for a secreted form of human CYP17. Further examples are likely and will extend our understanding of such metabolic effects on the ontogenesis of porphyria. Exposure of eukaryotic cells with exogenous ALA also increases URO due to insufficiency of decarboxylase (42) 
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